ViewRay

ViewRay develops advanced radiation therapy technology for the treatment of cancer. It designs, manufactures, and markets MRIdian, an MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian’s increased target accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who would not previously have been considered radiation therapy candidates. ViewRay believes MRIdian will significantly improve the safety and efficacy of radiation therapy, leading to improved patient outcomes with reduced side effects from off-target radiation delivery.

The company was incorporated in 2004 and is based in Cleveland, Ohio.

ViewRay headquartered in United States, North America, operates in the Biotechnology, Health Care, Manufacturing, Medical Device sector. The company focuses on Biotechnology and has secured $294.9B in funding across 336 round(s). With a team of 251-500 employees, ViewRay is actively contributing to advancements in Biotechnology. Their latest funding round, Series C - ViewRay, raised $20.0M. Discover more about their projects, partnerships, and impact on our platform.